


Article

# Tracking the Progression & Influence of Beta-Amyloid Plaques Using Percolation Centrality and Collective Influence Algorithm: A Study using PET Images

Gautam Kumar Baboo <sup>1</sup> , Raghav Prasad <sup>1</sup>, Pranav Mahajan <sup>1</sup> and Veeky Baths <sup>1,\*</sup>

<sup>1</sup> C-115, Cognitive Neuroscience Lab, Department of Biological Sciences, BITS-Pilani - K.K. Birla Goa Campus;

F. author p20130404@goa.bits-pilani.ac.in

S.author: f20170297@goa.bits-pilani.ac.in,

T. author: f20170277@goa.bits-pilani.ac.in

\* Correspondence: veeky@goa.bits-pilani.ac.in

**Abstract:** (1) Background: Network analysis allows investigators to explore the many facets of brain networks, particularly the proliferation of disease. One of the hypotheses behind the disruption in brain networks in Alzheimer's disease is the abnormal accumulation of beta-amyloid plaques and tau protein tangles. In this study, the potential use of percolation centrality to study beta-amyloid movement was studied as a feature of given PET image-based networks; (2) Methods: The PET image-based network construction is possible using a public access database - Alzheimer's Disease Neuroimaging Initiative, which provided 551 scans. For each image, the Julich atlas provides 121 regions of interest, which are the network nodes. Besides, using the collective influence algorithm, the influential nodes for each scan are calculated; (3) Analysis of variance ( $p < 0.05$ ) yields the region of interest Gray Matter Broca's Area for PiB tracer type for five nodal metrics. In comparison, AV45: the Gray Matter Hippocampus region is significant for three of the nodal metrics. Pairwise variance analysis between the clinical groups yields five and twelve statistically significant ROIs for AV45 and PiB, capable of distinguishing between pairs of clinical conditions. Multivariate linear regression between the percolation centrality values for nodes and psychometric assessment scores reveals Mini-Mental State Examination is reliable (4) Conclusion: percolation centrality effectively (41% of ROIs) indicates that the regions of interest that are part of the memory, visual-spatial skills, and language are crucial to the percolation of beta-amyloids within the brain network to the other widely used nodal metrics. Ranking the regions of interest based on the collective influence algorithm indicates the anatomical areas strongly influencing the beta-amyloid network.

**Keywords:** Brain Mapping; P.E.T.; Neurodegenerative Disorders; Alzheimer's Disease; Graph Theory; Percolation Centrality; Collective Influence.

**Citation:** Kumar B., Gautam.; Prasad, Raghav.; Mahajan, Pranav.; Baths, Veeky. Percolation Centrality and Collective Influence on Beta-amyloid plaques network. *Journal Not Specified* 2021, 1, 0. <https://doi.org/>

Received:  
Accepted:  
Published:

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Copyright:** © 2021 by the authors. Submitted to *Journal Not Specified* for possible open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

## 1. Introduction

Alzheimer's disease predominantly stands out when it comes to neurodegenerative diseases affecting the middle-age (early-onset Alzheimer's disease (A.D.)) and the old-age (Late-onset AD) human population. Current projections are estimated to cost about 2 trillion U.S. Dollars by 2030[1] affecting 75 million individuals by the same year. The indirect costs are estimated to be about 244 billion U.S. Dollars[2]. With no sight of a cure for A.D. and with increasing cases, early diagnosis and active management are the keys to tackling this disease for now. The ability to predict the disease's progression with high accuracy helps design a suitable treatment regime at an early stage, thereby bringing the disease's management to an affordable cost range.

The current methods of diagnosis of the disease include both non-invasive and invasive techniques of investigations ranging from Positron Emission Tomography (PET)

35 scans[3] or Cerebrospinal Fluid (CSF) analysis[4]. Positron Emission Tomography or PET  
36 imaging involves the use of radiopharmaceuticals such as 2-[18F], florbetapir-fluorine-18  
37 (AV45), or 11C-Pittsburgh compound B (PiB). AV45 and PiB[5] are comparatively newer  
38 and different in terms of the image construction mechanism. Both AV45 and PiB bind to  
39 beta-amyloid but vary in their half-life. AV45 has a half-life of 109.75 minutes and PiB,  
40 20 minutes[6]. A comparison between PiB and AV45 varies because AV45 shows uptake  
41 within the white matter regions[7].

42 A combination of techniques or criteria is currently employed to detect and de-  
43 termine the extent of dementia due to AD. Methods which include family history,  
44 psychiatric history for cognitive and behavioral changes, which is then followed by  
45 psychometric assessments such as Mini-Mental State Examination (MMSE)[8], Frontal  
46 Assessment Battery[9] and the Neuropsychiatric Inventory Questionnaire (NPIQ)[10].

47 The MMSE questionnaire provides assessment in five areas of cognitive function;  
48 Orientation, Attention, Memory, Language, and Visual-Spatial skills. Similarly, the NPI  
49 questionnaire provides assessment in twelve neuropsychiatric symptoms. These two  
50 questionnaires provide the classification of the patients into three clinical conditions;  
51 cognitively normal, mild cognitive impairment, and dementia due to A.D.

52 The application of network analysis/graph theory to anatomical neural networks  
53 has proved useful in understanding the brain connectivity[11,12](deviations under vari-  
54 ous psychological and neurological disease states. Network analysis on neuroimaging  
55 data such as EEG, MEG, fMRI, and PET scans proves to be useful to show the variation  
56 between a cognitively normal population versus other diagnostic states using various  
57 graph-theoretic metrics[13,14].

58 Graph metrics such as characteristic path length, clustering coefficient, modularity,  
59 and hubs have been studied and have provided insights into the brain networks of AD  
60 patients and control groups. Some studies have tried to map the progression of MCI  
61 to dementia due to AD[15,16]; thus, network analysis and the various graph metrics  
62 have shown potential as a tool to investigate the brain networks. Network analysis  
63 on AD is a practical application wherein it describes the Alzheimer's brain network's  
64 behaviour. Connectivity analysis using fMRI and EEG data reports provides mixed  
65 responses; when comparing AD patients and the control group[17], there is an increase  
66 or decrease in the network's connectivity. A reduction in connectivity could explain the  
67 cortical atrophy/disruption of the network. An increase could explain the compensatory  
68 mechanism[18].

69 Network Analysis on PET images related to A.D. mainly revolve around learning  
70 models or are limited to tracers that focus on the metabolic networks and the associated  
71 deviations of these networks[19,20]. Other methods include applying algorithms to the  
72 raw PET images to recognize patterns to resolve differences between healthy controls  
73 and patients with neurodegeneration[21]. The use of PET imaging and lumbar puncture  
74 to determine the levels of beta amyloids in either of them beyond the normal levels is  
75 the current standard of practice for the determination of dementia due to A.D.[22,23].

76 To understand beta-amyloid propagation, we propose applying graph theoretic  
77 methods on PET images to understand beta-amyloid advancement. The main benefit of  
78 adding this method is that

- 79 • This does not introduce any new steps for data collection from the patient and, at  
80 the same time.
- 81 • Adds value to the existing data by computing the percolation centrality of a given  
82 node at a given time

83 Network topology offers insights into the evolution of the network in a clinical  
84 setting. Studying such an evolution provides a possibility to understand the weak  
85 links within Julich atlas[24–26] based region of interest(ROI) networks. Such networks'  
86 structural connectivity information might yield the source and sink of neurodegeneration  
87 with the brain architecture.

88 Percolation centrality is defined as the proportion of ‘percolated paths’ that pass  
89 through that node; this measure quantifies the relative impact of nodes based on their  
90 topological connectivity, as well as their percolated states. In other words, it is one  
91 such graph metric that looks at the extent to which a given node within a network  
92 has percolated information or can percolate information(Figure 1). The volume of  
93 information transmitted via a given node is provided by values ranging from 0.0 to  
94 1.0[27,28]. Prior exploration of percolation centrality on disease networks[28–31] and  
95 percolation centrality in disease networks of the brain[32] have shown this as a promising  
96 metric for brain network investigation.

97 The knowledge on the application of percolation centrality on human PET-image-  
98 based networks is scarce at present. This work aims at adding knowledge to the gap.  
99 On the other hand, collective influence provides a minimum set of nodes or regions  
100 of the interest that can transfer information or spread disease with ease with optimal  
101 spread[33] based on the optimal percolation theory. By examining the network for the  
102 minimum set of nodes, this set will provide the regions of interest within the brain that  
103 optimally move beta-amyloid, disrupting the normal functioning of the existing neural  
104 networks.

105 Thus, the ability to detect the disease and predict the rate of progression of the  
106 disease at an early stage is imperative. To this end, the study aims to answer two main  
107 questions:

108 1) Can percolation centrality measure be used to determine the percolation of  
109 beta-amyloids within the brain?

110 2) Can the collective influence algorithm provide a minimum set of nodes that are  
111 vital to the AD network?

## 112 2. Materials and Methods

### 113 2.0.1. Patient Distribution

114 Based on the tracer agents used for acquiring the PET images, each diagnostic state  
115 subset of the data set is divided into the two available tracers; AV45[34] and PiB[6]. The  
116 patients are categorized as Cognitively normal, with Mild Cognitive Impairment, or  
117 having Alzheimer’s Disease (AD) based on the ADNI study’s psychometric assessments.  
118 Next, the PET image is matched with the patient’s diagnostic state at the time of the  
119 imaging procedure. This provided a set of observations for each type of tracer for each  
120 patient condition clinical group((Table 1). Finally, the resulting set of patients is matched  
121 with the demographic information providing 531 patients.

### 122 2.1. Network Construction and Processing

#### 123 2.1.1. PET Image preprocessing

124 Image preprocessing is carried out in two steps (Figure 2):

125 1. Combining individual frames of the PET image to form a 4D raw activity image.  
126 This is done using the `fslmerge` utility included in FSL[35].

127 2. The 4D raw activity image is converted to a 4D SUV image using the following  
128 formula:

$$129 \text{SUV} = \frac{c_{img}}{c_{inj}} \quad (1)$$

127 where  $c_{img}$  (Mbq ml<sup>-1</sup>) is given by the raw activity image and  $c_{inj} = \frac{ID}{BW}$ .  $ID$  (MBq)  
128 is the injection dose[36], and  $BW$  (g) is the body weight of the patient, considering  
129 the equivalency  $1g = 1ml$

130 3. Spatially realigning the PET frames to correct for motion. This was done using  
131 MCFLIRT.[37] The motion correction occurs with 6 DOF. The PET frames are  
132 realigned using the mean image as a template. The mean image is obtained by  
133 applying the motion correction parameters to the time series and averaging the  
134 volumes.

135 4. Coregistering the 4D SUV image from subject space to MNI[38] space. This is done  
136 using FreeSurfer[39]. The image used for coregistration is the MNI152\_T1\_2mm\_brain.  
137 To parallelize this operation, GNU Parallel[40] is used.

## 138 2.2. PET Image-based Network Construction

139 The network is constructed using the regions of interest (ROIs) from the Julich  
140 Atlas. This atlas provides 121 ROIs, which translates to 121 nodes or vertices in the  
141 network((Figure 3). Building networks from the preprocessed images requires the  
142 generation of adjacency matrices. The adjacency matrix is computed by calculating the  
143 method described below.

144 The Bivariate Pearson correlation performs poorly in cases of "confounding" or  
145 "chain" interactions. In such cases, partial correlation measures the direct connectivity  
146 between two nodes by estimating their correlation after regressing out effects from all  
147 the other nodes in the network, hence avoiding spurious effects in network modeling.  
148 Whereas in cases of "colliding" interactions, a partial correlation may induce a spurious  
149 correlation. Thus, Sanchez-Romero and Cole have introduced a combined multiple  
150 functional connectivity method[41].

151 The network is constructed by computing the pairwise partial correlation values of  
152 voxel intensities in the PET images to produce an initial adjacency matrix ( $matrix_{part}$ ). A  
153 second matrix ( $matrix_{bivar}$ ) is constructed by computing the bivariate correlation values  
154 of voxel intensities in the PET images. Now,  $matrix_{part}$  is modified using  $matrix_{bivar}$  as  
155 follows:

$$matrix_{part}(i, j) = \begin{cases} 0 & \text{if } matrix_{bivar}(i, j) = 0 \\ \text{no change} & \text{otherwise} \end{cases} \quad (2)$$

156 where  $matrix_{part}(i, j)$  and  $matrix_{bivar}(i, j)$  is the element at  $(i, j)$  in the respective  
157 matrices.  $matrix_{part}$  is now the combinedFC adjacency matrix that defines the net-  
158 work((Figure 4).

159 The partial correlation is calculated using the correlation between two residuals;  
160 the values are computed using  $N - 2$  ROIs as co-factors for every pair of ROIs[42]. The  
161 partial correlation values serve as the edge weights and constitute the values in the  
162 adjacency matrices.

163 Partial correlations are computed as correlation of residuals. The first order partial  
164 correlation ( $\rho_{ij.k}$ ) of  $x_i$  and  $x_j$ , controlling for  $x_k$  is given by [43].

$$corr(resid(i|k), resid(j|k)) = \frac{c_{ij} - c_{ik}v_k c_{kj}}{\sqrt{v_i - c_{ik}v_k c_{ki}} \sqrt{v_j - c_{jk}v_k c_{kj}}} \quad (3)$$

where  $c_{ij} = cov(x_i, x_j)$  and  $v_k = var(x_k)$  Further,

$$\rho_{ij.k} = \frac{\rho_{ij} - \rho_{ik}\rho_{jk}}{\sqrt{1 - \rho_{ik}^2} \sqrt{1 - \rho_{jk}^2}} \quad (4)$$

165 Since we are controlling for  $(N - 2)$  ROIs for each pair of ROIs  $ROI_i$  and  $ROI_j$ , we  
166 calculate the  $(N - 2)^{th}$  order partial correlation. This is calculated recursively as

For each  $ROI_k \in \mathbf{ROIs}$

$$\rho_{ij.\mathbf{ROIs}} = \frac{\rho_{ij.\mathbf{ROIs} \setminus \{k\}} - \rho_{ik.\mathbf{ROIs} \setminus \{k\}} \rho_{kj.\mathbf{ROIs} \setminus \{k\}}}{\sqrt{1 - \rho_{ik.\mathbf{ROIs} \setminus \{k\}}^2} \sqrt{1 - \rho_{kj.\mathbf{ROIs} \setminus \{k\}}^2}} \quad (5)$$

167 The base case of this recursive algorithm is given by equation 3. The estimation of  
168 partial correlations is a computationally intensive task, mainly due to the pre-calculation

169 of residuals before computing cross-correlation. And because the number of covariates is  
170 large; this calculation is done in a time-optimized manner using the R package ppcor[43].

171 Next, the adjacency matrices with set threshold; using a) data-driven threshold  
172 scheme based on Orthogonal Minimal Spanning Trees (OMSTs)[21,44,45]. Network  
173 threshold serves to remove inconsequential (or low-impact) edges and reduce the net-  
174 work complexity. And b) shortest path thresholding scheme [46]. This is done to compare  
175 between the two common schemes used for threshold.

176 The Networkx[47] Python library is used for network construction from the thresh-  
177 old adjacency matrices and subsequent percolation centrality computation and other  
178 graph metrics.

### 179 2.3. Percolation Centrality Computation

Percolation centrality is a nodal metric and is calculated for each node. The percola-  
tion centrality for each node  $v$  at time  $t$  is calculated as shown below:

$$PC^t(v) = \frac{1}{(N-2)} \sum_{s \neq v \neq r} \frac{\sigma_{s,r}(v)}{\sigma_{s,r}} \frac{x_s^t}{[\sum x_o^t] - x_o^t} \quad (6)$$

180 Where  $\sigma_{s,r}$  is the number of shortest paths between nodes  $s$  and  $r$  pass-through node  $v$ ,  
181  $x_i^t$  is the percolation state of node  $i$  at time  $t$ ,  
182  $x_i^t = 0$  indicates a non-percolated node and,  
183  $x_i^t = 1$  indicates a fully percolated node.

184 The percolation centrality value is calculated for each network using the inbuilt  
185 function of Networkx.(see supplementary data)

### 186 2.4. Collective Influence Algorithm

187 We define  $G(q)$  the fraction of occupied sites (or nodes) belonging to the gi-  
188 ant(largest) connected component. Percolation theory[48] tells us that if we choose  
189 these  $q$  fraction of nodes randomly, the network undergoes a structural collapse at a cer-  
190 tain critical fraction where the probability of existence of the giant connected component  
191 vanishes,  $G = 0$ . The optimal percolation problem is finding the minimum fraction  $q_c$  of  
192 nodes to be removed such that  $G(q_c) = 0$  i.e. the minimum fraction of "influencers" to  
193 fragment the network. For any fixed fraction  $q < q_c$ , we search for the configuration of  
194 removed nodes that provides the minimal non-zero giant connected component  $G$ . For  
195 further reading on how the problems of optimal immunization and spreading (optimal  
196 influencer problem) to the problem of minimizing the giant component of a network,  
197 i.e., optimal percolation problem, readers are encouraged to read [49].

198 The algorithm is on the basis that, given a network: the flow of information within  
199 the network is optimal with a minimum number of nodes that weigh heavily on the  
200 flow of information through the said network[33]. In the context of this investigation,  
201 the small sets of nodes/ROIs would prove to be vital in the movement of beta-amyloid  
202 plaques.

203 The core idea is that the overall functioning of a network in terms of the spread of  
204 information (or in our case, movement of beta-amyloid plaques) hinges on a specific  
205 set of nodes called influencers. This idea of finding the most influential nodes has been  
206 previously used in other contexts, for example, activating influential nodes in social  
207 networks to spread information[50] or de-activating or immunizing influential nodes to  
208 prevent large scale pandemics[30,51]. In recent applications to neuroscience, this method  
209 has been used to find nodes essential for global integration of a memory network in  
210 rodents[32]. Our work is the first to apply it to study the progression of AD, to the best  
211 of our knowledge. In the context of this investigation, these small sets of influential  
212 nodes/ROIs would prove to be vital in the movement of beta-amyloid plaques.

213 With the implementation of Collective Influence (CI) algorithm, it facilitates to  
214 pinpoint the most influential nodes, more efficiently than previously known heuristic

215 techniques. CI is an optimization algorithm that aims to find the minimal set of nodes  
216 that could fragment the network in optimal percolation, or in a sense, their removal  
217 would dismantle the network in many disconnected and non-extensive components.  
218 In percolation theory, if we remove nodes randomly, the network would undergo a  
219 structural collapse at a critical fraction where the probability that the giant connected  
220 component exists is  $G = 0$ . The optimal percolation is an optimization problem that  
221 attempts to find the minimal fraction of influencers  $q$  to achieve the result  $G(q) = 0$ .

## 222 2.5. Other Graph metrics

223 Besides the percolation centrality measure, four other nodal metrics of a graph are  
224 calculated here. Below are the four metrics that are computed for the PET image based  
225 graphs.

### 226 2.5.1. Betweenness Centrality

227 The basic definition of betweenness centrality is defined as,

$$C_B(u) = \frac{\sum_{s \neq u \neq t} \frac{\partial_{st}(u)}{\partial_{st}}}{(n-1)(n-2)/2} \quad (7)$$

228 This centrality information provides the uniqueness of it within the network. In  
229 this study it provides the regions of interest that play a vital role in the information flow  
230 in the network; the information being beta-amyloids or tau proteins accumulation in  
231 those regions.

### 232 2.5.2. Closeness Centrality

233 The closeness centrality of a node denotes how close a node is in the given network.  
234 It is inversely proportional to the farness of the node. Freeman defined the closeness  
235 centrality as,

$$C_c(u) = \frac{n-1}{\sum_{\forall u, v \neq u} d(u, v)} \quad (8)$$

236 The distance between two nodes/ROIs  $u$  and  $v$  in a network, denoted  $d(u, v)$ , is  
237 defined as the number of hops made along the shortest path between  $u$  and  $v$ . In this  
238 case, lesser the hops; closer are the two ROI's and the ease with which the misformed  
239 proteins can travel.

### 240 2.5.3. Current Flow Betweenness Centrality

241 Given a source ROI( $s$ ) and a target ROI( $t$ ), the absolute current flow through edge  
242  $(i, j)$  is the quantity  $A_{i,j} |v_i^{(s,t)} - v_j^{(s,t)}|$ . By Kirchoff's law the current that enters a node is  
243 equal to the current that leaves the node. Hence, the current flow  $F_i^{(s,t)}$  through a node  $i$   
244 different from the source  $s$  and a target  $t$  is half of the absolute flow on the edges incident  
245 in  $i$ :

$$246 \quad F_i^{(s,t)} = \frac{1}{2} \sum_j A_{i,j} |v_i^{(s,t)} - v_j^{(s,t)}|$$

247 Moreover, the current flows  $F_s^{(s,t)}$  and  $F_t^{(s,t)}$  through both  $s$  and  $t$  are set to 1, if  
248 end-points of a path are considered part of the path, or to 0 otherwise. Since the potential  
249  $v_i^{(s,t)} = G_{i,s}^+ - G_{i,t}^+$ , with  $G^+$  the generalized inverse of the graph Laplacian, the above  
250 equation can be expressed in terms of elements of  $G^+$  as follows:

$$251 \quad F_i^{(s,t)} = \frac{1}{2} \sum_j A_{i,j} |G_{i,s}^+ - G_{i,t}^+ + G_{j,t}^+ - G_{j,s}^+|$$

Finally, the current-flow betweenness centrality  $b_i$  of node  $i$  is the flow through  $i$  averaged over all source-target pairs  $(s, t)$ :

$$b_i = \frac{\sum_{s < t} F_i^{(s,t)}}{(1/2)n(n-1)} \quad (9)$$

#### 252 2.5.4. Eigenvector Centrality

253 Eigenvector centrality is a measure of the influence a node has on a network. If a  
254 node is pointed to by many nodes (which also have high Eigenvector centrality) then  
255 that node will have high Eigenvector centrality. In this case, the ROI's are the nodes  
256 and PET images provide the intensity value for each ROI, which helps in computing  
257 the centrality values each scan. Another interpretation to the centrality measure is that  
258 it provides the list of prominent regions in the brain network hierarchy and helps in  
259 detection of localized differences between patient populations[52].

260 Previous work on AD patients and comparison with normal patients provides the  
261 usefulness of Eigenvector centrality[53].

### 262 3. Statistical Analysis

263 For this study the null hypothesis is that percolation centrality value does not  
264 indicate the propagation of beta-amyloids within the brain network.

265 To determine the impact the percolation value has over each PET scan, a compar-  
266 ison with the regions of interest from the brain atlas is done using the Multiple linear  
267 regression analysis.

268 This study is exploratory in nature, and that the multiplicity problem is significant.  
269 And implementation of multiple test procedures does not solve the problem of making  
270 valid statistical inference for hypotheses that were generated by the data. But it does  
271 assist in describing the possible mechanism.

#### 272 3.1. Pairwise Analysis of Variance

273 To obtain pairwise group differences, we carry out a post prior (post hoc) analysis  
274 using scikit-posthocs package; the Student T-test pairwise gives us the respective p  
275 values. The ANOVA test is performed for each node in the network with the null  
276 hypothesis that the mean percolation centrality of that node is the same across the three  
277 stages. To test the null hypothesis, Analysis of variance with significance level ( $\alpha$ ) of 0.05  
278 is used.

#### 279 3.2. Error Correction

280 To control for multiple comparisons of 121 nodes, the Scheffe Test and control  
281 for Experiment-wise Error Rate (EER) is carried out. It is a single-step procedure that  
282 calculates the simultaneous confidence intervals for all pairwise differences between  
283 means.

#### 284 3.3. Multivariate Linear Regression

285 A correlation between the percolation centrality values for all 121 nodes and psy-  
286 chometric test scores - MMSE and NPIQ - is computed to identify the regions of interest  
287 that can be used as reliable predictors. Instead of performing multiple correlations across  
288 all three diagnoses, a multivariate regression analysis using regularisation techniques,  
289 wherein the features are the nodal percolation centrality values, and the target variable  
290 is the MMSE or NPIQ score. The goal is not to build a predictive model but to use it  
291 to quantify each node's influence in distinguishing between the clinical conditions for  
292 interpretation purposes. Had the purpose been building a machine learning model, it  
293 would imply the need to develop elaborate features sets (more than just percolation  
294 centrality) and utilize complex machine learning architectures (which provide less room  
295 for interpretability)

### 296 3.4. Regularization and Cross-Validation

297 We use regularization in our multivariate linear regression (MLR) to make sure our  
298 regression model generalizes better to unseen data. Regularization is necessary to control  
299 for overfitting. Here, both Lasso regression (L1 penalty) as well as Ridge regression  
300 (L2 penalty) are tested, and both provide similar root mean squared errors (RMSE) and  
301 similar desired results. We choose Lasso with  $\alpha = 0.1$ , for reporting our results (Figure 6).  
302 To quantify the robustness and reliability of our model, before and after regularization,  
303 we perform a leave one out cross-validation (LOOCV). We choose this cross-validation  
304 strategy because it is unbiased and better suited to our smaller sample sizes (especially in  
305 PiB tracer subset). We observe an improvement in validation RMSE with an increase in  
306 regularization (parameter  $\alpha$ ), but we also observe that excessive penalization of weights  
307 at very high values of  $\alpha$  can result in the regression model converging to the mean of  
308 the output MMSE/NPIQ scores. To take this into account, we also plot the standard  
309 deviation in predicted MMSE/NPIQ outputs and choose  $\alpha = 1$  for sufficient but not  
310 excessive regularization (Further details in supplementary figures).

## 311 4. Results

### 312 4.1. Pairwise ANOVA

313 The student t-test is performed on the resulting five centrality values for each  
314 tracer type and clinical conditions. There was a significant effect of the beta-amyloid  
315 accumulation on the five centrality values at  $p < 0.05$  level for the three clinical groups [ $F(3,$   
316  $454) = 3.002$  for AV45 and  $F(3, 97) = 3.027$  for PiB] (Table 2). A one-way between clinical  
317 groups ANOVA was conducted to compare the effect of beta-amyloid accumulation/tau  
318 protein on five centrality values in the cognitive normal, mild cognitive impairment and  
319 Alzheimer's disease patient (Table 3 & Table 4)).

#### 320 4.1.1. Cross-Validation and Regularization

321 Increasing regularization ( $\alpha$ ) improves the validation RMSE, making it more robust  
322 and generalize to unseen data. But at higher values of  $\alpha$ , it is observed that the standard  
323 deviation of predicted MMSE scores decreases to less than  $< 2$ , irrespective of clinical  
324 condition. Which could mean that it saturates to predicting the mean MMSE value when  
325 regression weights are extremely penalized. Thereby choosing a reasonably small yet  
326 effective  $\alpha$  value (less than 2), for which the validation RMSE and the standard deviation  
327 in output predicted MMSE.

### 328 4.2. Multivariate Linear regression

329 A linear regression model between the percolation centrality values for all 121 nodes  
330 and psychometric test scores - MMSE and NPIQ - is computed to identify the regions of  
331 interests that can be used as reliable predictors (Figure 4). Instead of performing multiple  
332 correlations across all three diagnoses, a multivariate regression analysis using leave  
333 one out cross validation is carried out, wherein the features are the nodal percolation  
334 centrality values and the target variable are the psychological assessment scores (Table 6  
335 & Table 7).

### 336 4.3. Comparison of Threshold Schemes

337 The two schemes are compared on the number of ROI's that can be considered  
338 on the basis of ANOVA analysis ( $p \leq 0.05$ ). The Juelich atlas has five clusters; frontal,  
339 parietal, temporal, occipital lobes and the white matter regions. As well as com-  
340 paring the performance of the threshold schemes between the two tracers (Table 5). Orthogonal  
341 Minimum Spanning Tree: provides a total of 112 ROI's across the five nodal metrics.  
342 On the Basis of the tracers, 60 ROI's are obtained for AV45 and 52 for PiB. Further, the  
343 ranking of ROI on the basis of the threshold scheme is listed for the three clinical groups  
344 for the respective tracers



345 Shortest Path Threshold: here a total of 66 ROI's are obtained. 31 and 35 for AV45  
346 and PiB tracers respectively. On the basis of the collective influence algorithm the ROI's  
347 are ranked for the three clinical groups and their respective tracers.

348 Further, comparing the number of statistically valid(MLR) ROIs across the five  
349 centrality values with the psychometric tests; MMSE and NPI-Q is performed. This  
350 helps in comparing the function of the ROI with the assessment carried out on the  
351 test(Table 5 Also see supplementary material-Tables 11 through 18).

#### 352 4.4. Other Graph Metrics

353 The Closeness Centrality provides the highest number of ROI's across overall(Table  
354 10); 80 in total. Eigenvector Centrality provides 33 ROI's(Table 9), whereas Percolation  
355 Centrality has 24 ROI's followed by the Betweenness Centrality measure with a total of  
356 23 ROI's and Current Flow Betweenness Centrality 19 ROI's across the two tracers(Table  
357 8).

#### 358 4.5. Collective Influence Ranking

359 The collective influence algorithm ranks the ROIs; here, the rank list is generated  
360 for the two tracers- AV45 and PiB. When a comparison of the rank is carried out between  
361 the clinical groups and tracers in the case of PiB, the ranking increases when moving  
362 from CN clinical condition to MCI, and then ranking decreases going from MCI to AD.  
363 Overall the ranking increases by 50% from cognitively normal condition to Alzheimer's  
364 disease condition.

#### 365 4.6. Demographics

366 On the basis of the selection criteria, 531 patients were available for this study. Of  
367 this, 48% of the females were of the Cognitively Normal group, 25% with Mild cognitive  
368 impairment, and 27% with Alzheimer's disease.

369 43% of the patients received more than 12 years of education as opposed to only  
370 16% who received less than 12 years of education, 31% received more than 12 years of  
371 education in the MCI group as opposed to 69% with less than 12 years of education.

372 47% of the Left-handed patients were in the AD clinical group as opposed to 26%  
373 in the right-handed patients. One patient in the MCI, two in CN, and four in AD groups  
374 were multilingual.

#### 375 4.7. Figures, Tables and Schemes







Figure 1. Generic example of a Percolation Network and Percolation Centrality




**Figure 2.** PET image preprocessing flowchart.




**Figure 3.** Analysis Pipeline



**Figure 4.** A connected network of all the nodes using the Juelich Atlas. Green circles indicate the ROIs, the connecting lines indicate the edges with their weights as denoted by the accompanying color bar



**Figure 5.** Illustrates the ROIs that corresponds to MMSE and NPIQ. The green circles represent ROIs associated with the MMSE psychometric assessment, the red circles represent ROIs associated with the NPIQ psychometric assessment, and the blue circles represent ROIs associated with both MMSE and NPIQ



**Figure 6.** Regularization using Lasso regression with L1 penalty.

Table 1: Distribution of patients

CN		MCI		AD	
AV45	PiB	AV45	PiB	AV45	PiB
262	13	76	65	116	19
M - 122	M - 8	M - 54	M - 45	M - 67	M - 11
F - 140	F - 5	F - 22	F - 20	F - 49	F - 8
Total - 275; M - 130, F - 145		Total - 141; M - 99, F - 42		Total - 135; M - 78, F - 57	

Table 2: Number of Scans per tracer type and corresponding critical F-values

Tracer	AV45	PiB
No. of scans	454	97
Critical F-value	3.002	3.027

Table 3: Pairwise ANOVA for AV45 & PiB tracers for Betweenness Centrality

Tracer Type	AV45			PiB		
	ROI	f-value	p-value	ROI	f-value	p-value
OMST	GM Premotor cortex BA6 R	5.94059	0.00283	GM Broca's area BA45 R	5.17524	0.00738
	GM Hippocampus subiculum L	4.96072	0.00738	GM Broca's area BA45 L	4.75064	0.01083
	GM Visual cortex V5 L	4.39253	0.01288	GM Anterior intraparietal sulcus hIP3 R	3.79312	0.02605
	GM Superior parietal lobule 7M L	4.34316	0.01352	GM Broca's area BA44 L	3.41149	0.03713
	GM Primary motor cortex BA4a L	3.73311	0.02463	GM Mammillary body	3.28404	0.04182
	GM Primary somatosensory cortex BA1 R	3.56446	0.02908			
	GM Primary auditory cortex TE1.2 R	3.31334	0.03725			
SPT	GM Insula Ig2 L	4.58607	0.01065	GM Broca's area BA44 R	6.22323	0.00290
	WM Acoustic radiation R	4.20148	0.01554	GM Primary auditory cortex TE1.2 R	5.14313	0.00759
	GM Hippocampus subiculum L	3.89671	0.02097	WM Cingulum R	4.61277	0.01227
	GM Mammillary body	3.63729	0.02707	GM Inferior parietal lobule PFcm R	3.96185	0.02229
	GM Inferior parietal lobule Pga R	3.04114	0.04872			

Table 4: Pairwise ANOVA for AV45 & PiB tracers for Percolation Centrality

Tracer Type	AV45			PiB		
	ROI	f-value	p-value	ROI	f-value	p-value
OMST	GM Premotor cortex BA6 R	5.87528	0.00302	GM Broca's area BA45 R	5.14527	0.00758
	GM Hippocampus subiculum L	4.85879	0.00815	GM Broca's area BA45 L	4.82934	0.01008
	GM Superior parietal lobule 7M L	4.48843	0.01172	GM Anterior intra-parietal sulcus hIP3 R	3.87541	0.02414
	GM Visual cortex V5 L	4.38407	0.01299	GM Broca's area BA44 L	3.42666	0.03661
	GM Anterior intra-parietal sulcus hIP1 L	4.14044	0.01650	GM Mamilary body	3.33030	0.04005
	GM Superior parietal lobule 7P R	3.83170	0.02235			
	GM Primary motor cortex BA4a L	3.77499	0.02364			
	GM Primary somatosensory cortex BA1 R	3.65131	0.02670			
	GM Primary auditory cortex TE1.2 R	3.34477	0.03611			
SPT	GM Insula Ig2 L	4.64660	0.01004	GM Broca's area BA44 R	6.30152	0.00270
	WM Acoustic radiation R	4.38388	0.01299	GM Primary auditory cortex TE1.2 R	5.03631	0.00836
	GM Hippocampus subiculum L	3.93752	0.02014	WM Cingulum R	4.57068	0.01275
	GM Mamilary body	3.54618	0.02961	GM Inferior parietal lobule PFcm R	3.94533	0.02263
	GM Inferior parietal lobule Pga R	3.17572	0.04266			
	GM Lateral geniculate body L	3.05960	0.04784			

Table 5: Distribution of ROI's across graph metrics and tracer type on the basis of ANOVA test.

Threshold Scheme	OMST		SPT	
	AV45	PiB	AV45	PiB
Tracer/ Centrality Measure				
BC	9	5	5	4
CC	33	29	10	6
CFBC	5	2	1	12
EVC	4	11	9	9
PC	9	5	6	4

378 BC: Betweenness Centrality, CC: Closeness Centrality, CFBC: Current Flow Betweenness Centrality, EVC:  
379 Eigenvector Centrality and PC: Percolation Centrality  
380

Table 6: Multivariate Linear Regression Analysis- Number of Region of Interest Across Clinical Conditions for Both Threshold Schemes for Betweenness Centrality

Graph Metric	Clinical Condition		CN		MCI		AD	
	PT	Tracer	OMST	SPT	OMST	SPT	OMST	SPT
Betweenness Centrality	MMSE	AV45	4	5	13	8	4	7
		PiB	5	4	5	1	2	9
	NPI-Q	AV45	0	3	1	1	0	0
		PiB	2	14	1	0	3	10

Table 7: Multivariate Linear Regression Analysis- Number of Region of Interest Across Clinical Conditions for Both Threshold Schemes for Percolation Centrality

Graph Metric	Clinical Condition		CN		MCI		AD	
	PT	Tracer	OMST	SPT	OMST	SPT	OMST	SPT
Percolation Centrality	MMSE	AV45	4	6	12	2	4	7
		PiB	5	3	5	0	2	9
	NPI-Q	AV45	6	3	2	1	0	0
		PiB	2	14	0	1	3	10

381 PT: Psychometric Assessment, OMST: Orthogonal Minimum Spanning Tree, SPT: Shortest Path Thresh-  
382 old, MMSE: Mini Mental State Examination, NPIQ: Neuropsychiatric Inventory Questionnaire Questionnaire  
383

## 384 5. Discussion

385 Here, a comparison of five nodal metrics; Betweenness centrality, closeness central-  
386 ity, current flow betweenness centrality, Eigenvector centrality, and percolation centrality,  
387 is carried out to better understand the study. Based on the variance analysis and multi-  
388 variate regression testing and the percolation centrality graph metric computed using  
389 the PET images, it is possible to show Alzheimer's disease progressing through the  
390 beta-amyloid/tau protein networks.

391 The student t-test provides nodes for each of the five centrality measures across the  
392 three clinical conditions, tracer types, and threshold schemes. Here, only the Current  
393 Flow Betweenness Centrality Measure fails to provide ROIs across all conditions (see  
394 tables 6 through 10), provides only three in cognitively normal condition and two in a  
395 mild cognitively impaired condition, both using the OMST scheme for threshold.

396 It is observed that percolation centrality values of certain areas of the brain, such  
397 as inferior and superior parietal lobules, are reliable for the tracer PiB. In contrast, for  
398 most other cases, the brain areas differ for each tracer considerably. The variation due

399 to the tracers could be because AV45 and PiB bind to the amyloids differently. It is also  
400 observed that the percolation centrality of Broca's area is a reliable differentiator between  
401 C.N. and A.D. clinical conditions, which validates previous findings that cognitive  
402 impairment affects speech production[54].

403 The MLR analysis for each of the centrality measures across the clinical conditions  
404 for both the tracer types provides, on average, one to two ROIs across conditions that  
405 can be considered as markers for studying Alzheimer's disease. Expect the current flow  
406 betweenness centrality measure, which performed poorly in this study providing only  
407 four(3-CN, 1-MCI) ROIs for both the threshold schemes and only one(MCI) ROI for  
408 AV45 and PiB tracers, respectively.

409 Further, when MLR is carried out for the NPI questionnaire, it provides fewer  
410 ROIs for each of the centrality measures. When comparing the contribution of ROIs  
411 for MMSE-related tasks and NPIQ related tasks. Percolation centrality has the highest  
412 percentage of 41% of ROIs. Followed by Closeness centrality with 40.5%, Betweenness  
413 centrality with 30%.

414 The results from the Scheffe test provide a means to validate and increase the  
415 confidence in the results—the leave one out cross-validation (LOOCV) strategy to test  
416 the robustness and reliability of our regression. Here cross-validation strategy is imple-  
417 mented because it is unbiased and better suited to our smaller sample size. Using the  
418 regularization (L1 - Lasso or L2 - Ridge) to control for overfitting, it is observed that  
419 increasing regularization on validation RMSE.

420 The ROIs obtained from the pairwise t-test for between the clinical conditions show  
421 that the OMST scheme provides a higher number of valid ROIs across the five centrality  
422 measures. In comparison between the two tracer types and threshold schemes, AV45  
423 provides 92 ROIs, whereas PiB gives 88 ROIs. Of this, 33.7% and 39.8% of the ROIs are  
424 based on the Shortest Path threshold scheme.

425 Previous studies show that the seeding of amyloid-beta occurs in neocortical and  
426 subcortical regions[55]; from this study, it is observed that for PiB, the following ROI -  
427 W.M. Superior occipito-frontal fascicle R is part of both the neocortical and subcortical  
428 regions of the brain. Apart from this, AV45 tracer has G.M. Medial geniculate body L  
429 ROI in the subcortical region and the following in the neocortical region -G.M. Superior  
430 parietal lobule 7P L, G.M. Anterior intra-parietal sulcus hIP3 R, G.M. Superior parietal  
431 lobule 7A L, and G.M. Superior parietal lobule 5L L, these are picked up with OMST  
432 scheme across all conditions when compared to SPT.

433 Prior research shows that damage to the parietal lobe is common in A.D., which can  
434 lead to apraxia[54,56], which is attested by these results. A.D. is associated with atrophy  
435 of the cornu ammonis, the subfield of the hippocampus, and deficits in episodic memory  
436 and spatial orientation[57–59]

437 And the following in the subcortical region - GM Amygdala-laterobasal group L,  
438 GM Amygdala-laterobasal group R and GM Hippocampus hippocampal- amygdaloid  
439 transition area R. Age factor not so important but the presence of beta amyloid deposits  
440 is[60], Since these ROIs stand out irrespective of the clinical condition or demographic  
441 backgrounds, the percolation centrality has a potential to be a reliable value for AD  
442 diagnosis, these ROIs are picked up by both tracers and threshold schemes.

443 Recent methods include genetic and protein markers to improve predicting the  
444 course of the disease[61], Genetic testing[62]for markers of A.D., the apolipoprotein-e4  
445 (APOE-e4)[63], or the use of blood testing or brain imaging to rule out dementia due to  
446 other factors. These methods rely on many data points and equally reliable computing  
447 hardware; this is currently a challenge.

448 Given that A.D. diagnosis is a global challenge, a method that works well in a  
449 spectrum of nations, from developed countries such as the United States to rural hospitals  
450 of southeast Asia or Africa[2] is necessary. Methods such as principal component analysis  
451 have a few drawbacks; for instance, choosing the number of principal components and  
452 data standardization for multiple PET scans of patients with different tracers leads

453 to controlling multiple variables. Or using regression analysis which is based on the  
454 assumption that there are cause and effect in place. Furthermore, a relationship that is  
455 present within a limited data set might get overturned with a detailed data set.

#### 456 5.0.1. Limitations

457 This study does not give any evidence regarding the disease progression in terms  
458 of the ROIs or patient clinical group. However, this can be addressed by increasing the  
459 number of observations within each patient clinical group.

460 The PET tracers used for acquiring the images, Pittsburgh Compound B (PiB) and  
461 Florbetapir (AV45), are compared to check for which among the two tracers provide  
462 a more consistent or reliable PC<sub>v</sub>. Here, the AV45 tracer binds with a high affinity to  
463 the beta-amyloid plaque, whereas PiB binds to oligomers or protofibrils. A possible  
464 explanation for the difference in PC<sub>v</sub> generated using these tracers would be their  
465 binding targets. The use of second-generation tracers can help improve the accuracy and  
466 test the applicability of percolation centrality on other neurodegenerative diseases and  
467 the possibility of using it in metastatic cancer scenarios.

468 Expanding the dataset to include more patients and comprehensive data that factors  
469 in healthy aging shrinkage of the brain, which results in a decrease of the distances of  
470 the brain networks, can help improve the reliability of the percolation centrality value.  
471 This can then provide a setting for testing out other psychological assessments that can  
472 be used as early indicators for dementia due to Alzheimer's disease, thereby tailoring it  
473 to specific demographics or population subsets.

474 The current pipeline is built for tracers such as AV45 and PiB, which indicate beta-  
475 amyloid plaque concentrations directly and as a post-hoc implementation. However,  
476 the pipeline can work with second-generation tracers and tracers like FDG with some  
477 appropriate modifications, namely: taking the multiplicative inverse of the percolation  
478 states of each of the ROIs to reflect the behavior of the FDG tracer.

479 A comparison of the ROIs across clinical conditions and tracers does not provide  
480 any new information at this stage regarding a common or group of common ROIs across  
481 the data(see Table 6. and 7.).

## 482 6. Conclusions

483 This study shows that percolation centrality is a reliable predictor and identifies  
484 the nodes that regulate the movement of beta-amyloid plaque and use them to track the  
485 disease.

486 This work demonstrates that using the existing neuroimaging method, PET-CT,  
487 can add value with relatively short computation time provided sufficient hardware  
488 capability is present. The ability to provide a metric to the extent of the disease state is  
489 advantageous to the current world of Alzheimer's. Prolonging life with modern-day  
490 medicine pushes patients to a world of medical experiences that deviate from the normal.  
491 Being able to show the deviation with a value such as percolation centrality has potential  
492 applications.

493 The reliability of percolation centrality can be improved by addressing the concerns  
494 that arise by the factors such as the number of patients and the number of patients within  
495 each clinical group, time points of data collection, demographics, and the PET tracers  
496 used were the limiting factors. Thus, this study provides the usability of percolation  
497 centrality value to determine the patient's state and sets the stage for studying other  
498 neurodegenerative diseases.

499 Unlike measures such as hub centrality or betweenness centrality, which provide  
500 information regarding a vital vertex/node within a network, the collective influence algo-  
501 rithm provides a minimum set of nodes of the network that are key to the beta-amyloid  
502 plaque movement, which can provide information regarding a particular pathway that  
503 is susceptible to the neuropathology.



504 The threshold schemes implemented in this study indicate that a data-driven ap-  
505 proach such as the Orthogonal Minimum Spanning Tree provides better results compared  
506 to the Shortest Path approach. Finally, we rank the ROIs based on influence in the net-  
507 work using the CI algorithm. We compare the results on two thresholding approaches,  
508 SPT and OMST, along with finding the influential nodes; this will help us gauge the reli-  
509 ability across different threshold schemes. CI algorithm gives a ranked list of influential  
510 nodes for each network (or each scan).

511 The rank of a node is then further calculated for each category as the sum of  
512 individuals ranks of that node for every scan-wise list, divided by the number of scans  
513 it occurs in. Nodes are then ranked accordingly in a given category. This provides a  
514 general ranking of nodes in a category (AD/MCI/CN) instead of looking at influential  
515 nodes in each scan separately. The results differ slightly based on the thresholding  
516 scheme adopted but broadly align with MLR results discussed earlier. Since this is an  
517 exploratory study, improving robustness across different thresholding schemes can be a  
518 possible future work.

519 **Supplementary Materials:** Please follow the link [https://www.mdpi.com//1/1/0/https://](https://www.mdpi.com//1/1/0/https://github.com/raghavprasad13/ADNI-Project)  
520 [github.com/raghavprasad13/ADNI-Project](https://www.mdpi.com//1/1/0/https://github.com/raghavprasad13/ADNI-Project) for the analysis pipeline code,  
521 and follow this link [https://www.mdpi.com//1/1/0/https://drive.google.com/file/d/1ZIVb6](https://www.mdpi.com//1/1/0/https://drive.google.com/file/d/1ZIVb6TFyJt68wb_N8mWgBr3xuhOcdZem/view?usp=sharing)  
522 [TFyJt68wb\\_N8mWgBr3xuhOcdZem/view?usp=sharing](https://www.mdpi.com//1/1/0/https://drive.google.com/file/d/1ZIVb6TFyJt68wb_N8mWgBr3xuhOcdZem/view?usp=sharing) for Tables 11 through 18.

523 **Author Contributions:** Conceptualization, Gautam and Veeky; methodology, Raghav and Gau-  
524 tam; validation, Gautam, Raghav and Pranav; formal analysis, Gautam, Raghav and Pranav;  
525 resources, Veeky Baths; data curation, Gautam and Raghav; writing—original draft preparation,  
526 Gautam; writing—review and editing, Gautam, Raghav, Pranav and Veeky; visualization, Raghav  
527 and Gautam; supervision, Veeky Baths; All authors have read and agreed to the published version  
528 of the manuscript.

529 **Funding:** This research received no funding.

530 **Institutional Review Board Statement:** Institutional Review Board Waiver Statement- Informed  
531 consent from the patients is obtained before the assessment carried out by the ADNI study team  
532 (See ADNI website for details), and this study is a secondary data analysis of the ADNI data  
533 collection, which aims at providing a simplified metric to an already diagnosed patient. The data  
534 access and usage is within the ADNI data use agreements.

535 **Informed Consent Statement:** Informed consent was obtained from all patients involved in the  
536 study by ADNI study Team(s).

537 **Data Availability Statement:** PET images from ADNI database are used in this study.

538 **Conflicts of Interest:** The authors declare no conflict of interest.

## 539 Abbreviations

540 The following abbreviations are used in this manuscript:

541

AD	Alzheimer Disease
ANOVA	Analysis of Variance
AV45	Florbetapir (18F- AV-45)
CI	Collective Influence
CN	Cognitively Normal
CSF	Cerebrospinal Fluid
DOF	Degrees of Freedom
EEG	Electroencephalography
FAB	Frontal Assessment Battery
fMRI	functional Magnetic Resonance Imaging
FSL	FMRIB Software Library
542 GNU	GNU's Not Unix
PCv	Percolation Centrality Value
PET	Positron Emission tomography
PiB	Pittsburgh compound B (11C-PIB)
RMSE	Root Mean Square Error
MCI	Mild Cognitive Impairment
MEG	Magnetoencephalography
MLR	Multivariate Linear Regression
MMSE	Mini-Mental State Examination
MST	Minimum Spanning Tree
NPIQ	Neuropsychiatric Inventory Questionnaire
OMST	Orthogonal Minimum Spanning Tree

543 **Appendix A.**

544 *Appendix A.1. Percolation Centrality Computation*

545 The percolation centrality value is calculated for each network using the inbuilt  
546 function of Networkx. This has a worst-case time complexity of  $O(n^3)$ , where n is the  
547 number of nodes in the network. Using a modified form of Brandes' fast algorithm  
548 for betweenness centrality, the complexity can be reduced to  $O(nm)$ , where m is the  
549 number of edges. However, percolation centrality calculation with target nodes cannot  
550 take advantage of this optimization and has a worst-case time complexity of  $O(n^3)$

551 *Appendix A.2. Other Graph Metrics-Tables*

Table 8: Multivariate Linear Regression Analysis- Region of Interest Across Clinical Conditions for Both Threshold Schemes for Current Flow Betweenness Centrality

Clinical Condition			CN		MCI		AD	
Graph Metric	PT	Tracer	OMST	SPT	OMST	SPT	OMST	SPT
Current Flow Betweenness Centrality	MMSE	AV45	3	0	1	0	0	0
		PiB	0	0	1	0	0	0
	NPI-Q	AV45	0	0	0	0	0	0
		PiB	0	0	0	0	0	0

Table 9: Multivariate Linear Regression Analysis- Region of Interest Across Clinical Conditions for Both Threshold Schemes for Eigenvector Centrality

Clinical Condition			CN		MCI		AD	
Graph Metric	PT	Tracer	OMST	SPT	OMST	SPT	OMST	SPT
Eigenvector Centrality	MMSE	AV45	2	2	11	4	7	10
		PiB	2	2	6	6	8	3
	NPI-Q	AV45	1	4	1	1	0	0
		PiB	3	0	3	3	2	9

Table 10: Multivariate Linear Regression Analysis- Region of Interest Across Clinical Conditions for Both Threshold Schemes for Closeness Centrality

Graph Metric	Clinical Condition		CN		MCI		AD	
	PT	Tracer	OMST	SPT	OMST	SPT	OMST	SPT
Closeness Centrality	MMSE	AV45	0	5	1	2	2	1
		PiB	2	4	46	0	6	0
	NPI-Q	AV45	1	0	0	2	0	0
		PiB	3	30	1	0	0	10

552 PT: Psychometric Assessment, OMST: Orthogonal Minimum Spanning Tree, SPT: Shortest Path Thresh-  
553 old, MMSE: Mini Mental State Examination, NPIQ: Neuropsychiatric Inventory Questionnaire Questionnaire




## References

1. El-Hayek, Y.H.; Wiley, R.E.; Khoury, C.P.; Daya, R.P.; Ballard, C.; Evans, A.R.; Karran, M.; Molinuevo, J.L.; Norton, M.; Atri, A. Tip of the Iceberg: Assessing the Global Socioeconomic Costs of Alzheimer's Disease and Related Dementias and Strategic Implications for Stakeholders. *Journal of Alzheimer's Disease* **2019**, *70*, 1–19. doi:10.3233/jad-190426.
2. 2020 Alzheimer's disease facts and figures. *Alzheimer's and Dementia* **2020**, *16*, 391–460. doi:10.1002/alz.12068.
3. Johnson, K.A.; Minoshima, S.; Bohnen, N.I.; Donohoe, K.J.; Foster, N.L.; Herscovitch, P.; Karlawish, J.H.; Rowe, C.C.; Carrillo, M.C.; Hartley, D.M.; Hedrick, S.; Pappas, V.; Thies, W.H. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. *Alzheimer's & dementia : the journal of the Alzheimer's Association* **2013**, *9*, e–1–16. doi:10.1016/j.jalz.2013.01.002.
4. Shaw, L.M.; Arias, J.; Blennow, K.; Galasko, D.; Molinuevo, J.L.; Salloway, S.; Schindler, S.; Carrillo, M.C.; Hendrix, J.A.; Ross, A.; Illes, J.; Ramus, C.; Fifer, S. Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease. *Alzheimer's & dementia : the journal of the Alzheimer's Association* **2018**, *14*, 1505–1521. doi:10.1016/j.jalz.2018.07.220.
5. Landau, S.M.; Thomas, B.A.; Thurfjell, L.; Schmidt, M.; Margolin, R.; Mintun, M.; Pontecorvo, M.; Baker, S.L.; Jagust, W.J.; Initiative, A.D.N. Amyloid PET imaging in Alzheimer's disease: a comparison of three radiotracers. *European journal of nuclear medicine and molecular imaging* **2014**, *41*, 1398–1407. doi:10.1007/s00259-014-2753-3.
6. Yamin, G.; Teplow, D.B. Pittsburgh Compound-B (PiB) binds amyloid  $\beta$ -protein protofibrils. *Journal of neurochemistry* **2017**, *140*, 210–215. doi:10.1111/jnc.13887.
7. Su, Y.; Flores, S.; Wang, G.; Hornbeck, R.C.; Speidel, B.; Joseph-Mathurin, N.; Vlassenko, A.G.; Gordon, B.A.; Koeppe, R.A.; Klunk, W.E.; Jack Jr., C.R.; Farlow, M.R.; Salloway, S.; Snider, B.J.; Berman, S.B.; Roberson, E.D.; Brosch, J.; Jimenez-Velazques, I.; van Dyck, C.H.; Galasko, D.; Yuan, S.H.; Jayadev, S.; Honig, L.S.; Gauthier, S.; Hsiung, G.Y.R.; Masellis, M.; Brooks, W.S.; Fulham, M.; Clarnette, R.; Masters, C.L.; Wallon, D.; Hannequin, D.; Dubois, B.; Pariente, J.; Sanchez-Valle, R.; Mummery, C.; Ringman, J.M.; Bottlaender, M.; Klein, G.; Milosavljevic-Ristic, S.; McDade, E.; Xiong, C.; Morris, J.C.; Bateman, R.J.; Benzinger, T.L. Comparison of Pittsburgh compound B and florbetapir in cross-sectional and longitudinal studies. *Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring* **2019**, *11*, 180–190, [<https://alz-journals.onlinelibrary.wiley.com/doi/pdf/10.1016/j.dadm.2018.12.008>]. doi:https://doi.org/10.1016/j.dadm.2018.12.008.
8. Tombaugh, T.N.; McDowell, I.; Kristjansson, B.; Hubble, A.M. Mini-Mental State Examination (MMSE) and the Modified MMSE (3MS): A psychometric comparison and normative data. *Psychological Assessment* **1996**, *8*, 48–59. doi:10.1037//1040-3590.8.1.48.
9. Dubois, B.; Slachevsky, A.; Litvan, I.; Pillon, B. The FAB: a Frontal Assessment Battery at bedside. *Neurology* **2000**, *55*, 1621–1626. doi:10.1212/wnl.55.11.1621.
10. Cummings, J.L.; Mega, M.; Gray, K.; Rosenberg-Thompson, S.; Carusi, D.A.; Gornbein, J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. *Neurology* **1994**, *44*, 2308–2314. doi:10.1212/wnl.44.12.2308.
11. Reijneveld, J.C.; Ponten, S.C.; Berendse, H.W.; Stam, C.J. The application of graph theoretical analysis to complex networks in the brain. *Clinical Neurophysiology* **2007**, *118*, 2317–2331. doi:10.1016/j.clinph.2007.08.010.
12. Stam, C.J.; Reijneveld, J.C. Graph theoretical analysis of complex networks in the brain, 2007. doi:10.1186/1753-4631-1-3.
13. Sakkalis, V. *Modern electroencephalographic assessment techniques: Theory and applications*; 2014; pp. 1–383. doi:10.1007/978-1-4939-1298-8.
14. Vecchio, F.; Miraglia, F.; Maria Rossini, P. Connectome: Graph theory application in functional brain network architecture. *Clinical Neurophysiology Practice* **2017**, *2*, 206–213. doi:10.1016/j.cnp.2017.09.003.
15. de Haan, W.; Mott, K.; van Straaten, E.C.; Scheltens, P.; Stam, C.J. Activity Dependent Degeneration Explains Hub Vulnerability in Alzheimer's Disease. *PLoS Computational Biology* **2012**, *8*, [[arXiv:10.1371/journal.pcbi.1002582](https://arxiv.org/abs/10.1371/journal.pcbi.1002582)]. doi:10.1371/journal.pcbi.1002582.
16. Tijms, B.M.; Wink, A.M.; de Haan, W.; van der Flier, W.M.; Stam, C.J.; Scheltens, P.; Barkhof, F. Alzheimer's disease: connecting findings from graph theoretical studies of brain networks. *Neurobiology of Aging* **2013**, *34*, 2023–2036. doi:10.1016/j.neurobiolaging.2013.02.020.

17. Tijms, B.M.; Wink, A.M.; de Haan, W.; van der Flier, W.M.; Stam, C.J.; Scheltens, P.; Barkhof, F. Alzheimer's disease: connecting findings from graph theoretical studies of brain networks. *Neurobiology of Aging* **2013**, *34*, 2023–2036. doi:10.1016/j.neurobiolaging.2013.02.020.
18. Wook Yoo, S.; Han, C.E.; Shin, J.S.; Won Seo, S.; Na, D.L.; Kaiser, M.; Jeong, Y.; Seong, J.K. A network flow-based analysis of cognitive reserve in normal ageing and Alzheimer's disease. *Scientific Reports* **2015**, *5*, 1–14. doi:10.1038/srep10057.
19. Chung, J.; Yoo, K.; Kim, E.; Na, D.L.; Jeong, Y. Glucose Metabolic Brain Networks in Early-Onset vs. Late-Onset Alzheimer's Disease, 2016.
20. Son, S.J.; Kim, J.; Seo, J.; min Lee, J.; Park, H. Connectivity analysis of normal and mild cognitive impairment patients based on FDG and PiB-PET images. *Neuroscience Research* **2015**, *98*, 50–58. doi:10.1016/j.neures.2015.04.002.
21. Klyuzhin, I.S.; Fu, J.F.; Hong, A.; Sacheli, M.; Shenkov, N.; Matarazzo, M.; Rahmim, A.; Jon Stoessl, A.; Sossi, V. Data-driven, voxel-based analysis of brain PET images: Application of PCA and LASSO methods to visualize and quantify patterns of neurodegeneration. *PLoS ONE* **2018**, *13*, 1–20. doi:10.1371/journal.pone.0206607.
22. McKhann, G.M.; Knopman, D.S.; Chertkow, H.; Hyman, B.T.; Jack, C.R.J.; Kawas, C.H.; Klunk, W.E.; Koroshetz, W.J.; Manly, J.J.; Mayeux, R.; Mohs, R.C.; Morris, J.C.; Rossor, M.N.; Scheltens, P.; Carrillo, M.C.; Thies, B.; Weintraub, S.; Phelps, C.H. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimer's & dementia : the journal of the Alzheimer's Association* **2011**, *7*, 263–269. doi:10.1016/j.jalz.2011.03.005.
23. Sperling, R.A.; Aisen, P.S.; Beckett, L.A.; Bennett, D.A.; Craft, S.; Fagan, A.M.; Iwatsubo, T.; Jack, C.R.J.; Kaye, J.; Montine, T.J.; Park, D.C.; Reiman, E.M.; Rowe, C.C.; Siemers, E.; Stern, Y.; Yaffe, K.; Carrillo, M.C.; Thies, B.; Morrison-Bogorad, M.; Wagster, M.V.; Phelps, C.H. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimer's & dementia : the journal of the Alzheimer's Association* **2011**, *7*, 280–292. doi:10.1016/j.jalz.2011.03.003.
24. Kötter, R.; Mazziotta, J.; Toga, A.; Evans, A.; Fox, P.; Lancaster, J.; Zilles, K.; Woods, R.; Paus, T.; Simpson, G.; Pike, B.; Holmes, C.; Collins, L.; Thompson, P.; MacDonald, D.; Iacoboni, M.; Schormann, T.; Amunts, K.; Palomero-Gallagher, N.; Geyer, S.; Parsons, L.; Narr, K.; Kabani, N.; Goualher, G.L.; Boomsma, D.; Cannon, T.; Kawashima, R.; Mazoyer, B. A probabilistic atlas and reference system for the human brain: International Consortium for Brain Mapping (ICBM). *Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences* **2001**, *356*, 1293–1322. doi:10.1098/rstb.2001.0915.
25. Eickhoff, S.B.; Stephan, K.E.; Mohlberg, H.; Grefkes, C.; Fink, G.R.; Amunts, K.; Zilles, K. A new SPM toolbox for combining probabilistic cytoarchitectonic maps and functional imaging data. *NeuroImage* **2005**, *25*, 1325–1335. doi:10.1016/j.neuroimage.2004.12.034.
26. Desikan, R.S.; Ségonne, F.; Fischl, B.; Quinn, B.T.; Dickerson, B.C.; Blacker, D.; Buckner, R.L.; Dale, A.M.; Maguire, R.P.; Hyman, B.T.; Albert, M.S.; Killiany, R.J. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. *NeuroImage* **2006**, *31*, 968–980. doi:10.1016/j.neuroimage.2006.01.021.
27. Newman, M.E.; Watts, D.J. Scaling and percolation in the small-world network model. *Physical Review E - Statistical Physics, Plasmas, Fluids, and Related Interdisciplinary Topics* **1999**, *60*, 7332–7342, [arXiv:cond-mat/9904419]. doi:10.1103/PhysRevE.60.7332.
28. Piraveenan, M.; Prokopenko, M.; Hossain, L. Percolation Centrality: Quantifying Graph-Theoretic Impact of Nodes during Percolation in Networks. *PLOS ONE* **2013**, *8*, e53095.
29. Moore, C.; Newman, M.E.J. Epidemics and percolation in small-world networks. *Physical Review E* **2000**, *61*, 5678–5682. doi:10.1103/PhysRevE.61.5678.
30. Newman, M.E.J. Spread of epidemic disease on networks. *Physical Review E* **2002**, *66*, 16128. doi:10.1103/PhysRevE.66.016128.
31. Sander, L.M.; Warren, C.P.; Sokolov, I.M.; Simon, C.; Koopman, J. Percolation on heterogeneous networks as a model for epidemics. *Mathematical biosciences* **2002**, *180*, 293–305. doi:10.1016/s0025-5564(02)00117-7.
32. Del Ferraro, G.; Moreno, A.; Min, B.; Morone, F.; Pérez-Ramírez, Ú.; Pérez-Cervera, L.; Parra, L.C.; Holodny, A.; Canals, S.; Makse, H.A. Finding influential nodes for integration in brain networks using optimal percolation theory. *Nature Communications* **2018**, *9*, [1806.07903]. doi:10.1038/s41467-018-04718-3.
33. Morone, F.; Min, B.; Bo, L.; Mari, R.; Makse, H.A. Collective Influence Algorithm to find influencers via optimal percolation in massively large social media. *Scientific reports* **2016**, *6*, 30062. doi:10.1038/srep30062.
34. Chopra, A.; Shan, L.; Eckelman, W.C.; Leung, K.; Latterner, M.; Bryant, S.H.; Menkens, A. Molecular Imaging and Contrast Agent Database (MICAD): evolution and progress. *Molecular imaging and biology* **2012**, *14*, 4–13. doi:10.1007/s11307-011-0521-3.
35. Jenkinson, M.; Beckmann, C.F.; Behrens, T.E.J.; Woolrich, M.W.; Smith, S.M. FSL. *NeuroImage* **2012**, *62*, 782–790. doi:10.1016/j.neuroimage.2011.09.015.
36. Initiative, A.D.N. PET Acquisition **2017**.
37. Jenkinson, M.; Bannister, P.; Brady, M.; Smith, S. Improved Optimization for the Robust and Accurate Linear Registration and Motion Correction of Brain Images. *NeuroImage* **2002**, *17*, 825 – 841. doi:https://doi.org/10.1006/nimg.2002.1132.
38. Vizza, P.; Tradigo, G.; Messina, D.; Cascini, G.L.; Veltri, P. Methodologies for the analysis and classification of PET neuroimages. *Network Modeling Analysis in Health Informatics and Bioinformatics* **2013**, *2*, 191–208. doi:10.1007/s13721-013-0035-9.
39. Reuter, M.; Schmansky, N.J.; Rosas, H.D.; Fischl, B. Within-subject template estimation for unbiased longitudinal image analysis. *NeuroImage* **2012**, *61*, 1402–1418. doi:10.1016/j.neuroimage.2012.02.084.


40. Tange, O. GNU Parallel 20200722 ('Privacy Shield') 2020. GNU Parallel is a general parallelizer to run multiple serial command line programs in parallel without changing them., doi:10.5281/zenodo.3956817.
41. Sanchez-Romero, R.; Cole, M.W. Combining multiple functional connectivity methods to improve causal inferences. *bioRxiv* 2020, [<https://www.biorxiv.org/content/early/2020/02/06/841890.full.pdf>]. doi:10.1101/841890.
42. Madigan, D. Graphical models in applied multivariate statistics, by J. Whittaker, John Wiley & Sons, New York, 1990, 448 pp. Price: \$59.95. *Networks* 1994, 24, 125. doi:10.1002/net.3230240213.
43. Kim, S. ppcor: An R Package for a Fast Calculation to Semi-partial Correlation Coefficients. *Communications for Statistical Applications and Methods* 2015, 22, 665–674. doi:10.5351/CSAM.2015.22.6.665.
44. Dimitriadis, S.I.; Salis, C.; Tarnanas, I.; Linden, D.E. Topological Filtering of Dynamic Functional Brain Networks Unfolds Informative Chronnectomics: A Novel Data-Driven Thresholding Scheme Based on Orthogonal Minimal Spanning Trees (OMSTs) , 2017.
45. Dimitriadis, S.I.; Antonakakis, M.; Simos, P.; Fletcher, J.M.; Papanicolaou, A.C. Data-Driven Topological Filtering Based on Orthogonal Minimal Spanning Trees: Application to Multigroup Magnetoencephalography Resting-State Connectivity. *Brain connectivity* 2017, 7, 661–670. doi:10.1089/brain.2017.0512.
46. Dimitriadis, S.I.; Laskaris, N.A.; Tsirka, V.; Vourkas, M.; Micheloyannis, S.; Fotopoulos, S. Tracking brain dynamics via time-dependent network analysis. *Journal of Neuroscience Methods* 2010, 193, 145–155. doi:<https://doi.org/10.1016/j.jneumeth.2010.08.027>.
47. Hagberg, A.A.; Schult, D.A.; Swart, P.J. Exploring Network Structure, Dynamics, and Function using NetworkX. Proceedings of the 7th Python in Science Conference; Varoquaux, G.; Vaught, T.; Millman, J., Eds.; , 2008; pp. 11–15.
48. Bollobás, B.; Bollobás, B.; Riordan, O.; Riordan, O. *Percolation*; Cambridge University Press, 2006.
49. Morone, F.; Makse, H.A. Influence maximization in complex networks through optimal percolation. *Nature* 2015, 524, 65–68.
50. Richardson, M.; Domingos, P. Mining Knowledge-Sharing Sites for Viral Marketing. Proceedings of the Eighth ACM SIGKDD International Conference on Knowledge Discovery and Data Mining; Association for Computing Machinery: New York, NY, USA, 2002; KDD '02, p. 61–70. doi:10.1145/775047.775057.
51. Pastor-Satorras, R.; Vespignani, A. Epidemic Spreading in Scale-Free Networks. *Phys. Rev. Lett.* 2001, 86, 3200–3203. doi:10.1103/PhysRevLett.86.3200.
52. Wink, A.M. Eigenvector Centrality Dynamics From Resting-State fMRI: Gender and Age Differences in Healthy Subjects. *Frontiers in Neuroscience* 2019, 13, 648. doi:10.3389/fnins.2019.00648.
53. Wink, A.M.; Tijms, B.M.; ten Kate, M.; Raspor, E.; de Munck, J.C.; Altena, E.; Ecaz-Torres, M.; Clerigue, M.; Estanga, A.; Garcia-Sebastian, M.; Izagirre, A.; Martinez-Lage Alvarez, P.; Villanua, J.; Barkhof, F.; Sanz-Arigita, E. Functional brain network centrality is related to APOE genotype in cognitively normal elderly. *Brain and Behavior* 2018, 8, e01080, [<https://onlinelibrary.wiley.com/doi/pdf/10.1002/brb3.1080>]. doi:<https://doi.org/10.1002/brb3.1080>.
54. Fernández, M.; Gobartt, A.L.; Balañá, M.; Group, C.S. Behavioural symptoms in patients with Alzheimer's disease and their association with cognitive impairment. *BMC neurology* 2010, 10, 87. doi:10.1186/1471-2377-10-87.
55. Jucker, M.; Walker, L.C. Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. *Nature* 2013, 501, 45–51. doi:10.1038/nature12481.
56. Kueper, J.K.; Speechley, M.; Lingum, N.R.; Montero-Odasso, M. Motor function and incident dementia: a systematic review and meta-analysis. *Age and Ageing* 2017, 46, 729–738. doi:10.1093/ageing/afx084.
57. Adler, D.H.; Wisse, L.E.; Ittyerah, R.; Pluta, J.B.; Ding, S.L.; Xie, L.; Wang, J.; Kadivar, S.; Robinson, J.L.; Schuck, T.; Trojanowski, J.Q.; Grossman, M.; Detre, J.A.; Elliott, M.A.; Toledo, J.B.; Liu, W.; Pickup, S.; Miller, M.I.; Das, S.R.; Wolk, D.A.; Yushkevich, P.A. Characterizing the human hippocampus in aging and Alzheimer's disease using a computational atlas derived from ex vivo MRI and histology. *Proceedings of the National Academy of Sciences of the United States of America* 2018, 115, 4252–4257. doi:10.1073/pnas.1801093115.
58. Masurkar, A.V. Towards a circuit-level understanding of hippocampal CA1 dysfunction in Alzheimer's disease across anatomical axes. *Journal of Alzheimer's disease & Parkinsonism* 2018, 8, 412.
59. Ogawa, M.; Sone, D.; Beheshti, I.; Maikusa, N.; Okita, K.; Takano, H.; Matsuda, H. Association between subfield volumes of the medial temporal lobe and cognitive assessments. *Heliyon* 2019, 5, e01828. doi:<https://doi.org/10.1016/j.heliyon.2019.e01828>.
60. Hamaguchi, T.; Eisele, Y.S.; Varvel, N.H.; Lamb, B.T.; Walker, L.C.; Jucker, M. The presence of A $\beta$  seeds, and not age per se, is critical to the initiation of A $\beta$  deposition in the brain. *Acta Neuropathologica* 2012, 123, 31–37. doi:10.1007/s00401-011-0912-1.
61. Nichols, E.; Szoëke, C.E.; Vollset, S.E.; Abbasi, N.; Abd-Allah, F.; Abdela, J.; Aichour, M.T.E.; Akinyemi, R.O.; Alahdab, F.; Asgedom, S.W.; Awasthi, A.; Barker-Collo, S.L.; Baune, B.T.; Béjot, Y.; Belachew, A.B.; Bennett, D.A.; Biadgo, B.; Bijani, A.; Bin Sayeed, M.S.; Brayne, C.; Carpenter, D.O.; Carvalho, F.; Catalá-López, F.; Cerin, E.; Choi, J.Y.J.; Dang, A.K.; Degefa, M.G.; Djalalinia, S.; Dubey, M.; Duken, E.E.; Edvardsson, D.; Endres, M.; Eskandarieh, S.; Faro, A.; Farzadfar, F.; Fereshtehnejad, S.M.; Fernandes, E.; Filip, I.; Fischer, F.; Gebre, A.K.; Geremew, D.; Ghasemi-Kasman, M.; Gnedovskaya, E.V.; Gupta, R.; Hachinski, V.; Hagos, T.B.; Hamidi, S.; Hankey, G.J.; Haro, J.M.; Hay, S.I.; Irvani, S.S.N.; Jha, R.P.; Jonas, J.B.; Kalani, R.; Karch, A.; Kasaeian, A.; Khader, Y.S.; Khalil, I.A.; Khan, E.A.; Khanna, T.; Khoja, T.A.; Khubchandani, J.; Kisa, A.; Kissimova-Skarbek, K.; Kivimäki, M.; Koyanagi, A.; Krohn, K.J.; Logroscino, G.; Lorkowski, S.; Majdan, M.; Malekzadeh, R.; März, W.; Massano, J.; Mengistu, G.; Meretoja, A.; Mohammadi, M.; Mohammadi-Khanaposhtani, M.; Mokdad, A.H.; Mondello, S.; Moradi, G.; Nagel, G.; Naghavi, M.; Naik, G.; Nguyen, L.H.; Nguyen, T.H.; Nirayo, Y.L.; Nixon, M.R.; Ofori-Asenso, R.; Ogbo, F.A.; Olagunju, A.T.; Owolabi, M.O.; Panda-Jonas, S.; Passos, V.M.A.; Pereira, D.M.; Pinilla-Monsalve, G.D.; Piradov, M.A.; Pond, C.D.; Poustchi, H.; Qorbani,

- M.; Radfar, A.; Reiner, R.C.; Robinson, S.R.; Roshandel, G.; Rostami, A.; Russ, T.C.; Sachdev, P.S.; Safari, H.; Safiri, S.; Sahathevan, R.; Salimi, Y.; Satpathy, M.; Sawhney, M.; Saylan, M.; Sepanlou, S.G.; Shafieesabet, A.; Shaikh, M.A.; Sahraian, M.A.; Shigematsu, M.; Shiri, R.; Shiue, I.; Silva, J.P.; Smith, M.; Sobhani, S.; Stein, D.J.; Tabarés-Seisdedos, R.; Tovani-Palone, M.R.; Tran, B.X.; Tran, T.T.; Tsegay, A.T.; Ullah, I.; Venketasubramanian, N.; Vlassov, V.; Wang, Y.P.; Weiss, J.; Westerman, R.; Wijeratne, T.; Wyper, G.M.; Yano, Y.; Yimer, E.M.; Yonemoto, N.; Yousefifard, M.; Zaidi, Z.; Zare, Z.; Vos, T.; Feigin, V.L.; Murray, C.J. Global, regional, and national burden of Alzheimer's disease and other dementias, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *The Lancet Neurology* **2019**, *18*, 88–106. doi:10.1016/S1474-4422(18)30403-4.
62. Loy, C.T.; Schofield, P.R.; Turner, A.M.; Kwok, J.B.J. Genetics of dementia. *Lancet (London, England)* **2014**, *383*, 828–840. doi:10.1016/S0140-6736(13)60630-3.
63. Holtzman, D.M.; Herz, J.; Bu, G. Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. *Cold Spring Harbor perspectives in medicine* **2012**, *2*, a006312. doi:10.1101/cshperspect.a006312.




Output of image preprocessing

Defining nodes using parcellization



Juelich atlas


Constructing edges using DensParcorr and combinedFC



Unthresholded network


Network analysis

Node-wise percolation centrality



Finding influential nodes using optimal percolation theory

List of influential nodes in descending order of influence



Stage 1: Preprocessing

Stage 2: Network construction

Stage 3 & 4: Network analysis and finding influential nodes



